18F-FES PET/CT in Imaging Patients With Desmoid Tumors

Stopped early · Early Phase 1

Conditions studied: Deep Fibromatosis/Desmoid Tumor, Familial Adenomatous Polyposis

In brief

This pilot clinical trial studies fluorine (F)-18 16 alpha-fluoroestradiol (18F-FES) positron emission tomography (PET)/computed tomography (CT) in imaging patients with desmoid tumors. 18F-FES binds to estrogen receptors, which are present on desmoid tumors, and gives off radiation that may be detected by PET and CT scans. The PET/CT scan forms an image that may show where tumor cells with estrogen receptors can be found in the body.

Key facts

Study ID

NCT02374931

Run by

Vanderbilt-Ingram Cancer Center

People needed

3

Starts

2015-04-01

Expected to finish

2017-12-01

Last updated by the study team

2019-10-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with biopsy-proven extra-abdominal desmoid tumors
• Not currently on estrogen medication for birth control, menopause, or other reason
• No anti-estrogen therapy for desmoid tumor within the past 6 months
• Both sporadic desmoid tumors and those associated with familial adenomatous polyposis (FAP) syndromes will be included

You may not qualify if…

• Pregnancy or nursing patients
• Patients who do not wish to participate

Where it is running

• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.